Robert Davis

Robert Davis, Chairman and CEO of Merck, shares insights on the FDA's approval of Keytruda's new injectable formulation, emphasizing its convenience and potential patient benefits. He discusses Merck's pricing strategy and commitment to ensuring access without hindering adoption. Meanwhile, media reporter Matt Belloni dives into the Jimmy Kimmel controversy, exploring its implications for late-night TV and the dynamics between networks and affiliates, particularly focusing on issues of free speech and contractual obligations.

Guests Matthew Miskin, Steve Center, and Robert Davis discuss market dependency on a dovish Fed, EV production outlook, and Merck's new lung disease drug. Topics include managing market expectations, Powell's financial policy approach, electric vehicle transition challenges, competition in the auto industry, innovative drug approval for pulmonary arterial hypertension, and drug pricing in healthcare.